Immudicon, LLC logo

Immudicon, LLC

Immudicon is a early-stage biotech company, developing immunotherapeutic vaccines and a novel vaccine intracellular delivery technology for the treatment of cancer and chronic disease.

Immudicon is also developing a device known as DiagnosMe for early detection of chronic diseases. The DiagnosMe device consists of a sweat collection device, a biosensor, and an iPhone application and built a color-based test for a specific protein found in sweat.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.immudicon.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
28 Sidney Street,MA 2139
Cambridge
United States
Email
Contact Number
+1 703-389-3339

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/immudicon” connections=”true” suffix=””]

Immudicon drug discovery platform is based on isolation of an immuno-protein linked to horseshoe crabs that functions in humans via complement-associated pathways in order to generate T-cells specific to tumor cells.

In past, Immudicon has raised $1.5M and has partnered under paid agreements with several industry collaborators including Novartis.